Bronchoalveolar lavage(BAL)has become an important technique in the diagnosis and treatment of respiratory diseases in children.In order to standardize the clinical application of BAL in children,the Branch of Pediatric Critical Care Physicians of Chinese Medical Association,in collaboration with other institutions,has developed the"Clinical practice guidelines for bronchoalveolar lavage in Chinese children(2024)"based on the principles of the World Health Organization guidelines and the formulation/revision principles of the Chinese clinical practice guidelines(2022 edition).This guideline provides 30 recommendations to guide the operational procedures of BAL in children.

Transparency Ecosystem for Research and Journals in Medicine (TERM) working group summarized the essential recommendations that should be considered to review and publish a high-quality guideline. These recommendations from editors and reviewers included 10 components of essential requirements: systematic review of existing relevant guidelines, guideline registration, guideline protocol, stakeholders, conflicts of interest, clinical questions, systematic reviews, recommendation consensus, guideline reporting and external review. TERM working group abbreviates them as PAGE (essential requirements for Publishing clinical prActice GuidelinEs), and recommends guideline authors, editors, and peer reviewers to use them for high-quality guidelines.
Humans ; Practice Guidelines as Topic

The outbreak of coronavirus disease 2019 (COVID-19) is serious and there is no effective treatment to date. In order to reduce the mortality of severe and critical COVID-19, experts from the first-line in related fields in China were organized to analyze, discuss and summarize the diagnosis and treatment of severe and critical COVID-19 patients in Wuhan and other severe epidemic areas, and formulate the expert consensus. The first edition was released on February 22, 2020, and the revised one on March 4, 2020.
Betacoronavirus ; COVID-19 ; China ; Consensus ; Coronavirus ; Coronavirus Infections/therapy* ; Humans ; Pandemics ; Pneumonia, Viral/therapy* ; SARS-CoV-2

Polymyxin, a polypeptide antibiotic, derived from the culture of bacillus polymucilis, was introduced in the 1950s and used in clinical practice, but was replaced by safer antimicrobials due to its renal toxicity. In the recent years, with the increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacilli infections, polymyxin is reintroduced into the clinic because it is assumed an important role in the treatment of MDR infections and XDR infections. In order to regulate the clinical applications of polymyxin, we organized experts in relevant fields to develop expert consensus on polymyxin for reference, including parameters like pharmacokinetics and pharmacodynamics, dosage and usage, contraindications and relative contraindications, clinical applications and adverse reactions.
Anti-Bacterial Agents ; China ; Consensus ; Drug-Related Side Effects and Adverse Reactions ; Gram-Negative Bacterial Infections ; Humans ; Polymyxins